In attendance
Andrew J. Buckler, MS (QIBA Program Director)
P. David Mozley, MD (Co-chair)
Lawrence Schwartz, MD (Co-chair)
Maria Athelogou, MD
Jon DeVries, MBA
Charles Fenimore, PhD
Kavita Garg, MD
David Gustafson, PhD
Philip Judy, PhD
Hyun Grace Kim, PhD
Michael McNitt-Gray, PhD
David Miller
James Mulshine, MD
Kevin O’Donnell
Nicholas Petrick, PhD
Ying Tang, PhD
RSNA
Fiona Miller
Joe Koudelik

Project Timeline (Gantt Chart) Overview (Mr Buckler)
- Feedback and resolution needed before field test ends for vCT Profile v1.0
- More discussion required to carry out a continuous feedback process; mid January to late February 2011
- Public comment (opportunity for people not part of QIBA) followed by field test (users and industry)
- Reach-out to customers-in-the-field via survey suggested
- At least one vendor (Definiens) already showing interest in developing a Profile compliant product as tangible sign that we’re accomplishing something of value
- Process map includes qualification, device clearance, and reimbursement; to be updated as qualification meetings with BQRT take place and formal consideration is given to other uses

Group 1A Update
- Group 1A work submitted for SPIE abstract submitted for publication
- Group 1A’s activity to collect and disseminate data for use is complete
- Group 1A publication is expected by end of February 2011

Group 1B Update
- More work required to obtain results; working on analysis phase now

Group 1C Update
- 1C on track resolving few remaining technical issues
- Unknowns still exist concerning reading task/process; next 1C call scheduled for Dec 15th to discuss these issues

Publishing of Results
- Publishing results takes time and may overburden group projects if this is necessary for completion
- Many academic circles only recognize a project complete once results are published
  o Published results may hold more favor with the FDA
- Decision not to hold-back forward momentum while pursuing publication
• Proposed model would (1) work towards obtaining results and (2) push for publishing; these model does not change any interdependencies within the Gantt chart
• Drs Mozley and Mulshine to discuss new publication opportunities vs. clinical forum offline

**Project (and funding) priorities**
• QC process specifications and compliance testing methods need to be included
• Practicality not important in prioritizing tasks, but group consensus is needed
  o e.g. Need to demonstrate value in reducing variance in Claims; education and marketing will prove important
• Need a product to use
• Need information important enough to change behavior
• Need protocols to improve clinical trials systematically

**NIBIB Funding Proposals - Priorities**
1) Support or inform the specifications of Claim 4 (via groundwork: Impact of various acquisition parameters on reproducibility of measurements
   a. Inter- and intra-observer variability in VIA. How consistent are the results?
   b. Technical: For CT, this might include system type, vendor, collimation, pitch, dose, FOV, recon kernel, recon slice thickness, etc. This should also consider spiral vs. nonspiral CT, contrast use, etc.)
   c. Protocol
2) QC program specification and compliance method
3) Clinical performance:
4) Compare to current response criteria (RECIST, WHO, etc)
5) Replace – or “just” augment – SLD and WHO?
6) Correlation coefficient to clinical endpoints+++++ how to eat an elephant? One bite at a time. How to complete a long project? Start early.
7) Algorithm characteristics not yet modeled enough to support Claim 6 (Claim language still needs drafting (accuracy and speed trade-off, automated and semi-automated)
8) Apply DICOM SR to this model
9) AIM standard being proposed from caBIG program

**Next steps:**
• Process map includes qualification, device clearance, and reimbursement; to be posted to the QIBA Wiki for reference
• Drs Mozley and Mulshine to discuss new publication opportunities vs. clinical forum offline
• Drs McNitt-Gray and Fenimore to email Mr Buckler approximate dates for project completion
• Next call scheduled for Monday, Dec 20, at 11 am CST